Novartis Drops Experimental Amyotrophic Lateral Sclerosis Drug After Mid-Stage Trial Failure
Bengaluru: Novartis has halted development of an experimental drug for amyotrophic lateral sclerosis after it failed to meet goals in a mid-stage study, marking the latest disappointment for the Swiss drugmaker this year.
This follows an earlier setback for a closely watched heart drug, last week's late-stage failure of a muscle-wasting drug, and the halt of eight of 10 studies for its rap-cel cell therapy this month after three patient deaths. These developments have intensified investor scrutiny of its pipeline.
Endpoints News and Bloomberg News reported the news earlier on Wednesday, which the company later confirmed in an emailed statement to Reuters, saying it was discontinuing development of the drug VHB937.
The drug, also called lifonebart, was being studied in patients with ALS, also called Lou Gehrig's disease. It is a neurodegenerative condition that affects how nerve cells communicate with muscles and leads to muscle weakness that worsens over time.
The company's U.S.-listed shares were marginally up.
The drug failed to meet both main and secondary goals in the mid-stage trial, which was evaluating the efficacy and safety of VHB937 in participants with early-stage ALS within two years of symptom onset.
The study had enrolled 251 patients, according to clinicaltrials.gov.
The drug aims to stabilize TREM2, a protein that helps regulate immune responses, inflammation and waste clearance in the brain.
Companies have been trying to develop TREM2 drug candidates but have faced failures. In 2024, Alector said its experimental drug failed in a mid-stage trial.
Novartis is also studying the drug in patients with Alzheimer's disease, a progressive brain disorder that slowly robs memory.
The clinical trials website shows the company is recruiting patients for the mid-stage trial.
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.